Neoplasm, Residual
16 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Neoplasms
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Blinatumomab for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| BLINATUMOMAB + Venetoclax for neoplasm, residual | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Circulating tumor DNA (ctDNA) testing + Datopotamab Deruxtecan for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ELI-002 2P for neoplasm, residual | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Folfoxiri for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| INCA33890 for neoplasm, residual | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LENALIDOMIDE + Acalabrutinib + OBINUTUZUMAB for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-Dose Radiation Therapy (LDRT) for neoplasm, residual | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| mFOLFOXIRI for neoplasm, residual | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Osimertinib for neoplasm, residual | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RITUXIMAB + LENALIDOMIDE + Acalabrutinib for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sugemalimab for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TAGRAXOFUSP + Azacitidine + Venetoclax for neoplasm, residual | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tisagenlecleucel for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tki + blinatumomab for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zymosan + α-lactalbumin vaccine for neoplasm, residual | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.